Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

PhRMA Releases Video on ‘How Medicines Can Curb Health Care Costs’

Washington, DC, August 31, 2015 ― The Pharmaceutical Research and Manufacturers of America (PhRMA) in June released a new video that explains how continued innovation has helped patients to live longer, healthier lives.

Shifting the treatment paradigm by slowing, treating and curing diseases has helped patients avoid expensive hospital care.

Medicines have helped raise the average U.S. life expectancy from 47 years in 1900 to 78 years.

  • Since its peak in 1991, the cancer death rate in the U.S. has fallen 22 percent and 2 of 3 patients diagnosed with cancer live at least 5 years following diagnosis.
  • And new hepatitis C therapies have cure rates above 90 percent and dramatically decrease the burden of the disease on the U.S. health care system and the economy.
  • Medicines can continue to save lives and be part of the solution to reducing medical spending, but only if we have a health care system that supports innovation and encourages the development of new treatments for Alzheimer’s disease and other costly conditions.

To watch PhRMA’s new video, click here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.  Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.